KITE-772 - Multiple Myeloma - Arcellx Announces Clinical Hold for its iMMagine-1 Phase 2 Clinical Program

The clinical hold was received on June 16, following a recent patient death. The company believes limitations on bridging therapy are a contributing factor and is working with FDA to amend the protocol to expand options for patients that are consistent with current clinical practice. The FDA has provided clearance to Arcellx to continue to dose patients who have undergone lymphodepletion.

Link to full press release